紫杉醇加顺铂治疗晚期非小细胞肺癌的临床疗效

目的 观察紫杉醇(PTX)加顺铂(DDP)联合化疗治疗晚期非小细胞肺癌的近期疗效。方法 PTX135～180mg／m^2静脉滴注，第1天；DDP40mg／次，静脉滴注，第1～3天。每21天为一个周期，连用2或3周期。结果 可评价疗效者46例．其中CR1例(2．2％)，PR16例(34．8％)，总有效率为37．0％。毒副反应主要是骨髓抑制和恶心呕吐。结论 PTX DDP治疗晚期非小细胞肺癌可获得较高疗效，毒副反应轻，是个较好的联合化疗方案。

A clinical study on paclitaxel plus cisplatin combined therapy in the treatment of non-small cell lung cancer

Objective To evaluate the results of combined chemotherapy with paclitaxel (PTX, taxol) plus cisplatin (DDP) in the treatment of advanced non small cell lung cancer (NSCLC). Methods From January 1997 to December 2002, forty seven patients with advanced non small cell lung cancer received PTX 135 180 mg/m 2 by intravenous infusion, on day 1, and DDP 40 mg/time by intravenous infusion,on days 1 3. The treatment was repeated every 3 weeks, up to 2 or 3 cycles. Results Forty six patients were evaluable for efficacy. One patient got complete response (2.2%), and 16 got partial response (34.8%), with an overall response rate of 37.0%. The main toxicities were myelosuppression, nausea and vomiting, and other side effects were mild. Conclusion A high response rate can be obtained in advanced NSCLC by PTX plus DDP. PTX is a promising antitumor agent with tolerable toxicity.